Search Results

IntelGenx Corp. announced positive results from a proof-of-concept study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm® platform in healthy dogs and cats.

IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the three- and twelve-month periods ended December 31, 2023.

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted abbreviated new drug application (“ANDA”) for Buprenorphine Buccal Film.

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that Montelukast VersaFilm® has been administered to the first Parkinson’s Disease (“PD”) patients in the Phase 2 (‘MONTPARK’) clinical trial.

IntelGenx Corp. announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock, par value $0.00001 per share, at an offering price of $10.00 per share, for a maximum Offering amount of $20,000,000.

IntelGenx Corp. announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A Convertible Cumulative Preferred Stock, par value $0.00001 per share, at an offering price of $10.00 per share, for a maximum Offering amount of $20,000,000.

IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.

IntelGenx Technologies Corp. announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors of the Company (the “ Board ”) effective December 2, 2023.

IntelGenx Technologies Corp. reported financial results for the third quarter ended September 30, 2023.

IntelGenx Corp. announced that it has entered into development and license agreements with a wholly-owned subsidiary of Covenant Animal Health Partners, LLC.